Delcath Systems, Inc. (NASDAQ:DCTH) Receives Consensus Rating of “Hold” from Brokerages

Delcath Systems, Inc. (NASDAQ:DCTH) has been assigned an average recommendation of “Hold” from the seven research firms that are covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $22.50.

A number of analysts have weighed in on DCTH shares. Weiss Ratings raised shares of Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, May 11th. BTIG Research dropped their target price on shares of Delcath Systems from $23.00 to $19.00 and set a “buy” rating on the stock in a report on Thursday, February 26th. Wall Street Zen cut shares of Delcath Systems from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Zacks Research cut shares of Delcath Systems from a “hold” rating to a “strong sell” rating in a report on Monday, May 11th. Finally, Evercore set a $27.00 target price on shares of Delcath Systems in a report on Thursday, February 26th.

Institutional Investors Weigh In On Delcath Systems

Several large investors have recently added to or reduced their stakes in DCTH. Millennium Management LLC increased its position in Delcath Systems by 34.1% in the first quarter. Millennium Management LLC now owns 422,066 shares of the company’s stock worth $5,373,000 after buying an additional 107,391 shares during the period. Goldman Sachs Group Inc. increased its position in Delcath Systems by 58.7% in the first quarter. Goldman Sachs Group Inc. now owns 123,487 shares of the company’s stock worth $1,572,000 after buying an additional 45,695 shares during the period. JPMorgan Chase & Co. increased its position in Delcath Systems by 229.1% in the second quarter. JPMorgan Chase & Co. now owns 168,245 shares of the company’s stock worth $2,288,000 after buying an additional 117,118 shares during the period. Legal & General Group Plc acquired a new stake in Delcath Systems in the second quarter worth $46,000. Finally, Rhumbline Advisers acquired a new stake in Delcath Systems in the second quarter worth $586,000. 61.12% of the stock is owned by institutional investors and hedge funds.

Delcath Systems Price Performance

Shares of DCTH opened at $11.69 on Wednesday. The stock has a market capitalization of $403.54 million, a PE ratio of 1,169.00 and a beta of 0.54. The business’s fifty day moving average price is $10.68 and its 200 day moving average price is $10.08. Delcath Systems has a 12-month low of $8.12 and a 12-month high of $16.56.

Delcath Systems (NASDAQ:DCTH) last released its earnings results on Thursday, May 7th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.07. The firm had revenue of $24.99 million during the quarter, compared to analyst estimates of $23.51 million. Delcath Systems had a net margin of 0.62% and a return on equity of 0.51%. As a group, research analysts anticipate that Delcath Systems will post -0.88 earnings per share for the current fiscal year.

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.